

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-34. (Canceled)

35. (Currently amended) An isolated polynucleotide comprising a smooth muscle cell myosin heavy chain (SM-MHC) promoter/enhancer, wherein the enhancer comprises nucleotides 5638-5860 of SEQ ID NO:16 or nucleotides 6862-7100 of SEQ ID NO:17, and the promoter comprises a heterologous TATA box or transcription initiation site, and wherein the promoter/enhancer initiates expression in a smooth muscle cell *in vivo* when introduced into an animal.

36. (Previously presented) The polynucleotide of claim 35, wherein the promoter comprises a CArG1 and/or a CArG2 motif.

37. (Currently amended) The polynucleotide of claim 35, wherein the enhancer is coupled to a minimal thymidine kinase (TK) promoter.

38. (Previously presented) The polynucleotide of claim 35, wherein the promoter is operably linked to a heterologous polynucleotide.

39. (Previously presented) The polynucleotide of claim 38, wherein the heterologous polynucleotide encodes a polypeptide.

40. (Currently amended) An isolated polynucleotide comprising a smooth muscle cell myosin heavy chain (SM-MHC) promoter/enhancer, wherein the promoter/enhancer sequence comprises SEQ ID NO:16 or SEQ ID NO:17, wherein:

Amdt. dated November 3, 2004

Amendment under 37 CFR 1.116 Expedited Procedure

Examining Group

a CArG2 motif is mutated and the promoter is expressed in mesenteric artery, airway, stomach, intestine and bladder but not aorta, coronary artery or vena cava when introduced into an animal; or

the intronic CArG motif at positions 5815-5825 of SEQ ID NO:16 or 7046-7056 of SEQ ID NO:17 is mutated and the promoter is expressed in coronary artery, mesenteric artery, vena cava, airway, stomach, intestine and bladder but not aorta when introduced into an animal.

41. (Currently amended) The polynucleotide of claim 40, wherein the promoter/enhancer comprises SEQ ID NO:16 and the CArG2 motif is mutated.

42. (Currently amended) The polynucleotide of claim 40, wherein the promoter/enhancer comprises SEQ ID NO:16 and the intronic CArG motif is mutated.

43. (Currently amended) The polynucleotide of claim 40 wherein the promoter is operably linked to a heterologous polynucleotide.

44. (Currently amended) The polynucleotide of claim 43, wherein the heterologous polynucleotide encodes a polypeptide.

45. (Currently amended) An isolated genetically engineered cell comprising the polynucleotide of claim 35 or 40.

46. (Previously presented) A composition comprising the polynucleotide of claims 35 or 40 in a pharmaceutically acceptable carrier.

47. (Currently amended) An isolated polynucleotide comprising a smooth muscle cell myosin heavy chain (SM-MHC) promoter/enhancer, wherein the promoter/enhancer sequence comprises:

nucleotides 1 to 9500 and 11,700 to 13,700 of SEQ ID NO:16 and does not comprise the intervening nucleotides 9501-11699 of SEQ ID NO:16; or

Amdt. dated November 3, 2004

Amendment under 37 CFR 1.116 Expedited Procedure

Examining Group

nucleotides 1 to 6700 and 9,500 to 15,800 of SEQ ID NO:16 and does not comprise the intervening nucleotides 6701-9499 of SEQ ID NO:16; and

wherein the promoter/enhancer comprises a mutated or unmutated CArG2 or intronic CArG motif and the promoter/enhancer initiates expression in pulmonary vascular and airway smooth muscle cells *in vivo* when introduced into an animal.

48. (Currently amended) The isolated polynucleotide of claim 47, wherein the promoter/enhancer comprises nucleotides 1 to 9500 and 11,700 to 13,700 of SEQ ID NO:16 and does not comprise the intervening nucleotides 9501-11699 of SEQ ID NO:16.

49. (Currently amended) The isolated polynucleotide of claim 47, wherein the promoter/enhancer comprises nucleotides 1 to 6700 and 9,500 to 15,800 of SEQ ID NO:16 and does not comprise the intervening nucleotides 6701-9499 of SEQ ID NO:16.

50. (Previously presented) The isolated polynucleotide of claim 47, wherein the promoter/enhancer initiates expression in gastrointestinal, airway, arteriolar, and bladder smooth muscle cells but does not initiate expression in vascular smooth muscle cells within large arteries.

51. (Previously presented) The isolated polynucleotide of claim 47, wherein the promoter/enhancer comprises a mutated CArG2 motif.

52. (Previously presented) The isolated polynucleotide of claim 47, wherein the promoter/enhancer comprises an unmutated CArG2 motif.

53. (Previously presented) The isolated polynucleotide of claim 47, wherein the promoter/enhancer comprises a mutated intronic CArG motif.

54. (Previously presented) The isolated polynucleotide of claim 47, wherein the promoter/enhancer comprises an unmutated intronic CArG motif.

Amdt. dated November 3, 2004

Amendment under 37 CFR 1.116 Expedited Procedure

Examining Group

55. (Previously presented) The isolated polynucleotide of claim 53, wherein the promoter/enhancer initiates selective expression in vascular smooth muscle in arterioles and airway smooth muscle.

56. (Previously presented) The isolated polynucleotide of claim 51, wherein the promoter/enhancer initiates selective expression in gastrointestinal smooth muscle.

57. (Currently amended) An isolated genetically engineered cell comprising the polynucleotide of claim 47.

58. (Previously presented) A composition comprising the polynucleotide of claim 47 in a pharmaceutically acceptable carrier.

59. (New) The polynucleotide of claim 35, wherein the enhancer comprises nucleotides 5638-5860 of SEQ ID NO:16.

60. (New) The polynucleotide of claim 35, wherein the enhancer comprises nucleotides 6862-7100 of SEQ ID NO:17.

61. (New) The polynucleotide of claim 40, wherein the promoter/enhancer comprises SEQ ID NO:17 and the CArG2 motif is mutated.

62. (New) The polynucleotide of claim 40, wherein the promoter/enhancer comprises SEQ ID NO:17 and the intronic CArG motif is mutated.

63. (Canceled)